Karlijn Hasaart
PhD student

Children with Down syndrome show a higher incidence of leukemia during the first years of life. However, the reason for this is not clear. During my PhD project I try to understand why patients with Down syndrome have an increased risk of developing leukemia by characterizing the somatic mutations in healthy cells of Down syndrome fetuses and Down syndrome associated leukemia samples. Besides, I study the mutational consequences of chemotherapy on healthy hematopoietic cells of Down syndrome leukemia patients to understand why patients with Down syndrome suffer from increased treatment related side effects.